COEP

Coeptis Therapeutics Holdings Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website coeptistx.com
Employees(FY) 4
ISIN US19207A1088

Performance

-23.92%

-27.32%

-23.55%

-56.41%

-81.95%

YTD

-83.72%

Profile

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of COEP 2024-12-20

The stock indicators suggest a predominantly bearish sentiment, with a Moving Average Score of 3 indicating strong downward momentum, while the Oscillators Score of 50 reflects a neutral stance. Overall, the Technical Score of 26 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of COEP

Stock Rank

Recent News & Updates

2024-12-11 19:00
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies(Prnewswire)
2024-12-02 19:15
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries(Prnewswire)
2024-11-06 19:07
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development(Prnewswire)
2024-10-23 20:07
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use(Prnewswire)
2024-10-14 20:07
Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy(Prnewswire)
2024-09-18 19:07
Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing(Prnewswire)
2024-09-04 20:07
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders(Prnewswire)
2024-08-16 08:52
COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024(Investorplace)
2024-06-19 20:47
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering(Prnewswire)
2024-05-29 20:47
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting(Prnewswire)
2024-05-12 21:53
COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024(Investorplace)
2024-05-07 20:47
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024(Prnewswire)
2024-05-01 20:47
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting(Prnewswire)
2024-04-01 20:47
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award(Prnewswire)
2024-02-25 20:00
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK(Prnewswire)
2024-02-06 18:30
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections(Prnewswire)
2024-01-03 18:30
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024(Prnewswire)
2023-12-05 18:00
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now(Globenewswire)
2023-12-04 18:00
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now(Globenewswire)
2023-12-03 18:30
Coeptis Therapeutics to Present at the Emerging Growth Conference(Prnewswire)
2023-10-30 21:01
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023(Prnewswire)
2023-10-30 19:00
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now(Globenewswire)
2023-10-23 20:30
Coeptis Therapeutics Announces $2 Million Private Placement(Prnewswire)
2023-10-10 19:30
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology(Prnewswire)
2023-10-08 21:15
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies(Prnewswire)
2023-10-03 19:30
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting(Prnewswire)
2023-10-02 19:00
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now(Globenewswire)
2023-09-26 19:30
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa(Prnewswire)
2023-09-13 19:30
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection(Yahoo Finance)
2023-09-10 19:30
Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.